User Tools

Site Tools


diffuse_astrocytoma

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
diffuse_astrocytoma [2018/03/20 10:20]
administrador
diffuse_astrocytoma [2018/03/20 18:43] (current)
administrador
Line 3: Line 3:
 ====Types==== ====Types====
  
-Diffuse astrocytoma ​[[IDH]] [[Wild type]]+[[Diffuse astrocytoma]] [[IDH Mutant]] 9400/3
  
-Diffuse ​astrocytoma ​NOS+[[Gemistocytic ​astrocytoma]] 9411/3
  
-[[Diffuse astrocytoma]] [[IDH Mutant]]+[[Diffuse astrocytoma]] [[IDH wild type]] 9400/3 
 + 
 +[[Diffuse astrocytoma]] [[NOS]] 9400/3 
 + 
 +----
  
--- Gemistocytic astrocytoma IDH Mutant 
  
 WHO grade determinations are still made on the basis of histologic criteria. Another reason why phenotype remains essential is that, as mentioned above there are individual tumors that do not meet the more narrowly defined phenotype and genotype criteria, e.g., the rare phenotypically classical diffuse astrocytoma that lacks the signature genetic characteristics of IDH and [[ATRX]] mutations. Nevertheless,​ it remains possible that future WHO classifications of the diffuse gliomas, in the setting of deeper and broader genomic capabilities,​ will require less histological evaluation—perhaps only a diagnosis of “diffuse glioma.” For now, the 2016 CNS WHO is predicated on the basis of combined phenotypic and genotypic classification,​ and on the generation of “integrated” diagnoses. WHO grade determinations are still made on the basis of histologic criteria. Another reason why phenotype remains essential is that, as mentioned above there are individual tumors that do not meet the more narrowly defined phenotype and genotype criteria, e.g., the rare phenotypically classical diffuse astrocytoma that lacks the signature genetic characteristics of IDH and [[ATRX]] mutations. Nevertheless,​ it remains possible that future WHO classifications of the diffuse gliomas, in the setting of deeper and broader genomic capabilities,​ will require less histological evaluation—perhaps only a diagnosis of “diffuse glioma.” For now, the 2016 CNS WHO is predicated on the basis of combined phenotypic and genotypic classification,​ and on the generation of “integrated” diagnoses.
diffuse_astrocytoma.txt · Last modified: 2018/03/20 18:43 by administrador